These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 14682278)

  • 21. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 22. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
    Mascolini M
    AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Highlights of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    Prescott LM
    Body Posit; 2002 Dec; 15(7):16-20. PubMed ID: 14989207
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
    Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
    J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Confirmed NRTI remains an important therapy option. Didanosine effective despite multiple resistance to NRTIs].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():21. PubMed ID: 15373039
    [No Abstract]   [Full Text] [Related]  

  • 28. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
    Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
    Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea for HIV infection.
    Zachary KC; Davis B
    AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintaining a low viral load with Nevirapine?
    TreatmentUpdate; 1998 Dec; 10(10):3-4. PubMed ID: 11366017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
    J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Didanosine--stability as backbone drug].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():83-4. PubMed ID: 16385888
    [No Abstract]   [Full Text] [Related]  

  • 33. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
    Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meeting notes from ICAAC. Ritonavir-boosted tipranavir proves beneficial in treatment-experienced patients.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):5-6. PubMed ID: 15717371
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Some competition for 1592.
    GMHC Treat Issues; 1997; 11(4/5):10-1. PubMed ID: 11364373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
    James JS
    AIDS Treat News; 1995 Dec; (no 236):7. PubMed ID: 11363052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation of antiretroviral therapy: implications of recent findings.
    Saag MS
    Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.
    Tseng AL; Salit IE
    Ann Pharmacother; 2007 Mar; 41(3):512-7. PubMed ID: 17341536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.